What the CagriSema trials showed The REDEFINE 1 trial published in the New England Journal of Medicine delivered remarkable numbers
E Tommolino, Medscape
Hypoglycaemia can occur with GLP-1 agonists, especially if used alongside sulfonylureas or insulin.3 Diabetics on GLP-1 Agonists can also present with episodes of hyperglycaemia and DKA.3 In such cases, it is important to look beyond the acute management and consider whether problems with regular access to medication is a contributing factor
This can create the necessary headspace and opportunity to cultivate healthier habits around nutrition, physical activity, and overall well-being
C-peptide levels are measured instead of insulin levels because C-peptide can assess a person's own insulin secretion even if they receive insulin injections, and because the liver metabolizes a large and variable amount of insulin secreted into the portal vein but does not metabolize C-peptide, meaning blood C-peptide may be a better measure of portal insulin secretion than insulin itself
CDMOs and large biopharma dominate purchasing volume, focusing on validated supply and lifecycle economics
